Article Text

Download PDFPDF

Original article
Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study
  1. Alan Moss1,2,
  2. Stephen J Williams1,
  3. Luke F Hourigan4,
  4. Gregor Brown3,5,
  5. William Tam6,
  6. Rajvinder Singh6,
  7. Simon Zanati2,5,
  8. Nicholas G Burgess1,7,
  9. Rebecca Sonson1,
  10. Karen Byth8,
  11. Michael J Bourke1,7
  1. 1Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, Australia
  2. 2Department of Endoscopy, Western Health and The University of Melbourne, Melbourne, Australia
  3. 3Department of Gastroenterology, The Epworth Hospital, Melbourne, Australia
  4. 4Department of Gastroenterology, Princess Alexandra Hospital, Brisbane, Australia
  5. 5Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia
  6. 6Department of Gastroenterology, Lyell McEwin Hospital, Adelaide, Australia
  7. 7Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia
  8. 8Medical Statistician, Research and Education Network, Westmead Hospital and Sydney University, Sydney, New South Wales, Australia
  1. Correspondence to Professor Michael J Bourke, Director of Gastrointestinal Endoscopy, Department of Gastroenterology and Hepatology, Westmead Hospital, c/- Suite 106a, 151-155 Hawkesbury Road, Westmead, Sydney, New South Wales 2143, Australia; michael{at}


Objective Wide-field endoscopic mucosal resection (WF-EMR) is an alternative to surgery for treatment of advanced colonic mucosal neoplasia up to 120 mm in size, but has been criticised for its potentially high recurrence rates. We aimed to quantify recurrence at 4 months (early) and 16 months (late) following successful WF-EMR and identify its risk factors and clinical significance.

Design Ongoing multicentre, prospective, intention-to-treat analysis of sessile or laterally spreading colonic lesions ≥20 mm in size referred for WF-EMR to seven academic endoscopy units. Surveillance colonoscopy (SC) was performed 4 months (SC1) and 16 months (SC2) after WF-EMR, with photographic documentation and biopsy of the scar.

Results 1134 consecutive patients were enrolled when 1000 successful EMRs were achieved, of whom 799 have undergone SC1. 670 were normal. Early recurrent/residual adenoma was present in 128 (16.0%, 95% CI 13.6% to 18.7%). One case was unknown. The recurrent/residual adenoma was diminutive in 71.7% of cases. On multivariable analysis, risk factors were lesion size >40 mm, use of argon plasma coagulation and intraprocedural bleeding. Of 670 with normal SC1, 426 have undergone SC2, with late recurrence present in 17 cases (4.0%, 95% CI 2.4% to 6.2%). Overall, recurrent/residual adenoma was successfully treated endoscopically in 135 of 145 cases (93.1%, 95% CI 88.1% to 96.4%). If the initial EMR was deemed successful and did not contain submucosal invasion requiring surgery, 98.1% (95% CI 96.6% to 99.0%) were adenoma-free and had avoided surgery at 16 months following EMR.

Conclusions Following colonic WF-EMR, early recurrent/residual adenoma occurs in 16%, and is usually unifocal and diminutive. Risk factors were identified. Late recurrence occurs in 4%. Overall, recurrence was managed endoscopically in 93% of cases. Recurrence is not a significant clinical problem following WF-EMR, as with strict colonoscopic surveillance, it can be managed endoscopically with high success rates.

Trial registration number: NCT01368289.

  • Endoscopic Polypectomy
  • Colonic Polyps
  • Colonoscopy
  • Adenoma
  • Colorectal Cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.